Septerna Inc SEPN:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:00 PM EDT30.55UNCH (UNCH)
Volume
5,544
Close
30.55
+0.61 (+2.04%)
+0.61 (+2.04%)Volume
281,010
52 week range
9.70 - 32.63
- Open29.89
- Day High30.84
- Day Low29.57
- Prev Close29.94
- 52 Week High32.63
- 52 Week High Date02/25/26
- 52 Week Low9.70
- 52 Week Low Date06/05/25
Latest On Septerna Inc
- Fast Money: MO, SEP, BUD, DHI
CNBC.com
Key Stats
- Market Cap1.377B
- Shares Out45.08M
- 10 Day Average Volume0.32M
- Dividend-
- Dividend Yield-
- Beta-
Latest On Septerna Inc
- Fast Money: MO, SEP, BUD, DHICNBC.com
KEY STATS
- Open29.89
- Day High30.84
- Day Low29.57
- Prev Close29.94
- 52 Week High32.63
- 52 Week High Date02/25/26
- 52 Week Low9.70
- 52 Week Low Date06/05/25
- Market Cap1.377B
- Shares Out45.08M
- 10 Day Average Volume0.32M
- Dividend-
- Dividend Yield-
- Beta-
RATIOS/PROFITABILITY
- EPS (TTM)-0.82
- P/E (TTM)-37.39
- Fwd P/E (NTM)-12.99
- EBITDA (TTM)-66.559M
- ROE (TTM)-9.26%
- Revenue (TTM)72.255M
- Gross Margin (TTM)-
- Net Margin (TTM)-49.88%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORESepterna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover...
Jeffrey Tong Ph.D.
Chairman of the Board
Jeffrey Finer M.D., Ph.D.
Chief Executive Officer, Director
Elizabeth Bhatt
President
Gil Labrucherie
Chief Financial Officer
Address
250 East Grand Avenue, Suite 65
South San Francisco, CA
94080
United States